Immpact's bispecific CAR T-cell therapy IMPT-314 cleared to enter clinic for B-cell lymphoma

Jan. 25, 2023

Immpact Bio USA Inc. has announced clearance of its IND application by the FDA for IMPT-314, a bispecific OR-Gate autologous chimeric antigen receptor (CAR) T-cell therapy targeting the B-cell antigens CD19 and CD20.

BioWorld Science CAR T Immuno-oncology FDA IND

Today's news in brief

BioWorld

BioWorld briefs for May 31, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for May 31, 2023.

FDA approved icons and medical professional

Genmab, Abbvie to join Roche with FDA nod for CD20 bispecific in lymphoma

BioWorld

Five months after the first anti-CD20xCD3 T-cell engaging bispecific antibody, Roche Holding AG’s Lunsumio (mosunetuzumab), cleared U.S. FDA approval for...

Gene therapy to reverse T2D shows proof of concept at ASGCT

BioWorld

The most ambitious objective of any treatment is to eradicate the disease, acting on its origin to cure it instead of treating its symptoms. This is the purpose...

Medtronic, Philips, Edwards late-breaking study data spotlighted at EuroPCR

BioWorld MedTech

Among the many companies presenting data at the EuroPCR conference in Paris, several late breaking trials from heavy hitters Medtronic plc, Royal Phillips NV and...

Upgrade your daily dose of biopharma and medtech news

Immpact's bispecific CAR T-cell therapy IMPT-314 cleared to enter clinic for B-cell lymphoma